Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions
- 1 January 2000
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 49 (S1), 35-42
- https://doi.org/10.1046/j.1365-2125.2000.00151.x
Abstract
Aims To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study. Methods In vitro metabolism of [14C]-ziprasidone was studied using human liver microsomes. The metabolites were identified using mass spectrometry. The kinetics of metabolite formation were determined using [14C]-ziprasidone (10–200 μm) over 5 min, and Km and Vmax were estimated from Lineweaver-Burk plots. IC50 values for the inhibition of specific probe substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, by ziprasidone, risperidone and 9-hydroxyrisperidone were also determined using human liver microsomes from three subjects. Mean Ki values were calculated. Results Three CYP-mediated metabolites – ziprasidone sulphoxide, ziprasidone sulphone and oxindole acetic acid – were identified. The apparent Km and Vmax values for the formation of the major metabolite, ziprasidone sulphoxide (measured as the sum of sulphoxide and sulphone) were 235 μm and 1.14 nmol mg− 1 protein min− 1, respectively. Isoform-selective inhibitors and recombinant enzymes indicated that CYP3A4 is responsible for the formation of ziprasidone metabolites. Ziprasidone was not a substrate for the other isoforms studied. Similar in vitro inhibition of CYP2D6 (Ki 6.9–16 μm) and CYP3A4 (Ki 64–80 μm) was obtained with ziprasidone, risperidone and 9-hydroxyrisperidone. The in vivo free drug concentrations associated with clinically effective doses of ziprasidone are at least 1500-fold lower than the mean Ki for either CYP2D6 inhibition or CYP3A4 inhibition. Conclusions Ziprasidone is predominantly metabolized by CYP3A4 in human liver microsomes and is not expected to mediate drug interactions with coadministered CYP substrates, at clinically effective doses.Keywords
This publication has 28 references indexed in Scilit:
- The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacidBritish Journal of Clinical Pharmacology, 2000
- Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizersBritish Journal of Clinical Pharmacology, 2000
- Use of in vitro human metabolism studies in drug developmentBiochemical Pharmacology, 1994
- Synthesis of 3H- and 14C-labelled CP-88,059: A potent atypical antipsychotic agentJournal of Labelled Compounds and Radiopharmaceuticals, 1994
- The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and NomenclatureDNA and Cell Biology, 1993
- In Vitro Methods for Assessing Human Hepatic Drug Metabolism: Their use in Drug DevelopmentDrug Metabolism Reviews, 1993
- Tolbutamide hydroxylation by human liver microsomes: Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidationsBiochemical Pharmacology, 1988
- Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450Archives of Biochemistry and Biophysics, 1987
- Measurement of protein using bicinchoninic acidAnalytical Biochemistry, 1985
- Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism of the β-carbolines harmine and harmolBiochemical Pharmacology, 1983